SecBot SecBot

TELA

TELA Bio, Inc.
Nasdaq· Surgical & Medical Instruments & Apparatus· Inc. DE· CIK 0001561921 Healthcare & Medical Devices
$0.7620 −0.06 (−7.07%)
Nov 16 4:00 PM ET · prev $0.8200
Market cap
$38.9M
Nano cap
Consensus
Buy
82% Buy or better · 11 analysts
Median target
🔒 Subscribers only
1 year
−33.2%
from $1.14 · Nov 17
30 days
−21.4%
from $0.9700
52-week range
$0.5600–1.41
−46% from high · low Apr 13
Avg volume 20D
146.3K
Nov 11 spike 773.4K
Short interest
579.6K
≈1.3% of shares · −9.3%
Days to cover
5.1
at average volume
Insider net
+$186.0K
2 buyers · 0 sellers · since Feb 20
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
17
analyzed by SecBot
SecBot read BEARISH 9 reports · 90 days
Balance 2 bearish · 1 bullish · 1 mixed · 5 neutral oldest → newest, height = score
Avg score ·High conf. 7/9

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    2 insiders bought $186.0K at an average $1.05. No open-market sales. Price is 27% below their cost.

  • InstitutionsMIXED

    Q3 2026: 5 added (0 new), 4 trimmed or exited.

  • AnalystsBULLISH

    9 of 11 rate it Buy or better.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.150 → −$0.160 over 90 days. 4 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest −9.3% to 579.6K shares. 5.1 days to cover, ≈1.3% of shares.

  • TrendDOWNTREND

    26% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
JANE STREET GROUP, LLCADD81,737$94.0K
MORGAN STANLEYDOUBLED70,000$80.5K
UBS Group AGTRIM15,756$18.1K
CITIGROUP INCADD3,039$3.5K
JPMORGAN CHASE & CODOUBLED1,089$1.4K
Steward Partners Investment Advisory, LLCTRIM995$1.1K
SIMPLEX TRADING, LLCTRIM644$740.00
BARCLAYS PLCNEAR_EXIT6$7.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

11 analysts
Buy 82% rate it Buy or better
Strong Buy3Buy6Hold2Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Sep 25, 2026Craig-Hallum
INITIATE
INITIATEBuy

Insider ledger

Form 4
$186.0K
bought · 2 insiders
$0
sold · 0 insiders
−27.3%
vs their $1.05 cost
DateInsiderTypeValue
Oct 15, 2026
Plovanic William J.
Director
Oct 15, 2026
AWARD$16.2K
Oct 15, 2026
Capper Joseph H
Director
Oct 15, 2026
AWARD$20.0K
Sep 17, 2026
Capper Joseph H
Director
Sep 17, 2026
BUY$30.5K
Sep 16, 2026
Capper Joseph H
Director
Sep 16, 2026
BUY$58.3K
Sep 15, 2026
Capper Joseph H
Director
Sep 15, 2026
BUY$52.9K
Sep 14, 2026
Capper Joseph H
Director
Sep 14, 2026
BUY$25.5K
Aug 17, 2026
Getz Heather C
Chief Executive Officer
Aug 17, 2026
BUY$8.3K
Aug 14, 2026
Getz Heather C
Chief Executive Officer
Aug 14, 2026
BUY$10.5K

Earnings setup

Estimates
−$0.16
EPS estimate, this quarter
−7%
estimate change, 90 days
4↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.16-$0.21–-$0.13-1.3%$20.0M
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
579,565
shares short
-9.3%
vs prior settlement
5.1
days to cover
≈1.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 13, 2026 SEC
Nantahala Capital Management filed an amended Schedule 13G disclosing beneficial ownership of 6,545,596 shares of TELA…
SC 13G/A · Impact 2/10
Nov 13, 2026 SEC
North Run Capital, LP filed an amended Schedule 13G disclosing beneficial ownership of 3,528,296 shares of TELA Bio…
SC 13G/A · Impact 2/10
Nov 10, 2026 Earnings
TELA Bio Reports Third Quarter 2026 Financial Results
Reduced sequential operating loss by 21%, including cost of realignment
Oct 27, 2026 Press
TELA Bio announced it will report Q3 2026 financial results on November 10, 2026, with a conference call and webcast…
Impact 2/10
Oct 15, 2026 Insider
Plovanic William J. was granted 16,089 shares
Director @ $1.01 ($16.2K)
Oct 15, 2026 Insider
Capper Joseph H was granted 19,801 shares
Director @ $1.01 ($20.0K)
Sep 30, 2026 Inst.
JANE STREET GROUP, LLC · ADD
81,737 shares ($94.0K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Nov 10, 2026
Earnings
TELA Bio Reports Third Quarter 2026 Financial Results
Reduced sequential operating loss by 21%, including cost of realignment
Nov 10, 2026
Earnings result
TELA Q3 2026 Earnings: EPS $-0.13 (+20.5% vs est)
Nov 6, 2026
Press release
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Nov. 06, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on…
Oct 27, 2026
Announcement
TELA Bio to Announce Third Quarter 2026 Financial Results
MALVERN, Pa., Oct. 27, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on…
Aug 31, 2026
Leadership
TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative
Company to reduce annual operating expenses by $17.0 million or 18% as part of broader efficiency program Company to reduce annual operating…

SecBot reports

17 filings · 3 press releases · 1 bullish · 4 bearish · 3 mixed · 9 neutral
All TELA filing & press-release reports (20)